Kelly Boothe

Contatto Relazioni con gli Investitori presso Carmot Therapeutics, Inc.

Health Technology

Profilo

Kelly Boothe is currently the Vice President of Investor Relations & Communications at Carmot Therapeutics, Inc. Prior to this role, Dr. Boothe worked as the Senior Director of Communications & Investor Relations at Spyre Therapeutics, Inc.

Posizioni attive di Kelly Boothe

Società	Posizione	Inizio
Carmot Therapeutics, Inc. Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA.	Contatto Relazioni con gli Investitori	-

Tutte le posizioni attive di Kelly Boothe

Precedenti posizioni note di Kelly Boothe

Società	Posizione	Fine
SPYRE THERAPEUTICS, INC.	Contatto Relazioni con gli Investitori	-

Vedi nel dettaglio l'esperienza di Kelly Boothe

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Kelly Boothe

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Società quotate in Borsa	1
SPYRE THERAPEUTICS, INC.	Health Technology

Aziende private	1
Carmot Therapeutics, Inc. Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA.	Health Technology